{"component": "definition", "props": {"groups": [{"size": 5, "samples": [{"hash": "abPECKgSdh0", "uri": "/contracts/abPECKgSdh0#current-product", "label": "Asset and Stock Purchase Agreement", "score": 31.3408622742, "published": true}, {"hash": "iIKFZ4D5YQO", "uri": "/contracts/iIKFZ4D5YQO#current-product", "label": "Asset and Stock Purchase Agreement (Texas Instruments Inc)", "score": 23.1464748383, "published": true}, {"hash": "ixECzWN990Q", "uri": "/contracts/ixECzWN990Q#current-product", "label": "Asset and Stock Purchase Agreement (Sensata Technologies Holland, B.V.)", "score": 21.0, "published": true}], "snippet": "means any (i) Sensor Product or Control Product, or any component thereof, that was manufactured, marketed, sold, offered for sale, distributed or otherwise transferred by the Business, or with respect to which the Business has substantially completed its development efforts, as of the Closing Date and (ii) future Sensor Product, Control Product or component that is an extension, modification, derivation, replacement or successor of such Sensor Product, Control Product or component and does not infringe or misappropriate Intellectual Property Rights of a third party in a manner that is materially different from its predecessor.", "snippet_links": [{"key": "offered-for-sale", "type": "definition", "offset": [114, 130]}, {"key": "the-business", "type": "clause", "offset": [172, 184]}, {"key": "with-respect-to", "type": "clause", "offset": [189, 204]}, {"key": "substantially-completed", "type": "clause", "offset": [228, 251]}, {"key": "development-efforts", "type": "clause", "offset": [256, 275]}, {"key": "as-of-the-closing-date", "type": "clause", "offset": [277, 299]}, {"key": "rights-of", "type": "definition", "offset": [549, 558]}, {"key": "a-third-party", "type": "clause", "offset": [559, 572]}], "hash": "0ca4bdd4077da3eb3ac07bbe0d1b35e8", "id": 1}, {"size": 3, "samples": [{"hash": "5sjZ0s11lyY", "uri": "/contracts/5sjZ0s11lyY#current-product", "label": "License and Development Agreement (Collegium Pharmaceutical, Inc)", "score": 27.6091709137, "published": true}, {"hash": "9AIc4DOAWE6", "uri": "/contracts/9AIc4DOAWE6#current-product", "label": "License and Development Agreement (Biodelivery Sciences International Inc)", "score": 27.6036968231, "published": true}, {"hash": "8MlfZxJ25vx", "uri": "https://ir.collegiumpharma.com/static-files/b8134e31-7f07-45c3-bae8-2a32180ad7c8", "label": "ir.collegiumpharma.com", "score": 7.7091035843, "published": false}], "snippet": "means that certain Licensed Product that is the subject of NDA 022266 (the \u201cCurrent Product NDA\u201d).", "snippet_links": [{"key": "licensed-product", "type": "definition", "offset": [19, 35]}, {"key": "subject-of", "type": "clause", "offset": [48, 58]}, {"key": "product-nda", "type": "definition", "offset": [84, 95]}], "hash": "8d2323e3ddb3c4a582f2f6dca0d15578", "id": 2}, {"size": 3, "samples": [{"hash": "3d45mDsC9xI", "uri": "https://www.gsaadvantage.gov/ref_text/GS35F455AA/0YB8QI.3U1LL6_GS-35F-455AA_SESGSA7020230606.PDF", "label": "www.gsaadvantage.gov", "score": 11.7132101059, "published": false}, {"hash": "hrZHsRwL9Vz", "uri": "https://www.gsaadvantage.gov/ref_text/GS35F455AA/0VY5GV.3ROIFM_GS-35F-455AA_SESGSA70.PDF", "label": "www.gsaadvantage.gov", "score": 10.4017791748, "published": false}, {"hash": "9r0Mxqrf6Ha", "uri": "https://cdn2.hubspot.net/hubfs/3341329/Collabware%20Documents/Support%20and%20Maintenance%20Program%202019-01-01%20-%20Policy.pdf", "label": "cdn2.hubspot.net", "score": 9.5201911926, "published": false}], "snippet": "means those software products which have not been discontinued or retired by Collabware, and for which Collabware offers standard support and maintenance services. A Current Product may become an End of Life Product at Collabware\u2019s sole discretion.", "snippet_links": [{"key": "software-products", "type": "clause", "offset": [12, 29]}, {"key": "support-and-maintenance-services", "type": "definition", "offset": [130, 162]}, {"key": "end-of-life-product", "type": "definition", "offset": [196, 215]}, {"key": "sole-discretion", "type": "definition", "offset": [232, 247]}], "hash": "68c95b88c88593427e211725b27a7b37", "id": 3}, {"size": 3, "samples": [{"hash": "d5Usmz7GOXU", "uri": "/contracts/d5Usmz7GOXU#current-product", "label": "Asset Purchase Agreement", "score": 31.3408622742, "published": true}, {"hash": "g3aeSXi39IB", "uri": "/contracts/g3aeSXi39IB#current-product", "label": "Asset Purchase Agreement (Medivation, Inc.)", "score": 26.7631759644, "published": true}, {"hash": "9lfTzDSR9Gf", "uri": "/contracts/9lfTzDSR9Gf#current-product", "label": "Asset Purchase Agreement (Biomarin Pharmaceutical Inc)", "score": 26.7631759644, "published": true}], "snippet": "means the form and formulation of the Product being administered as of the Signing Date in the On-Going Clinical Trials.", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [34, 45]}, {"key": "signing-date", "type": "definition", "offset": [75, 87]}, {"key": "clinical-trials", "type": "definition", "offset": [104, 119]}], "hash": "172d1a498781ce416eb67db071f9e3ec", "id": 4}, {"size": 3, "samples": [{"hash": "8vRlcWewcFQ", "uri": "/contracts/8vRlcWewcFQ#current-product", "label": "Licensing Agreement (Gilead Sciences Inc)", "score": 21.0, "published": true}, {"hash": "hli3jigqxin", "uri": "http://investors.gilead.com/static-files/538a7125-9214-4cc0-8700-d496d4727311", "label": "investors.gilead.com", "score": 9.4859685898, "published": false}], "snippet": "means the ten (10) milligram dosage formulation of ADV that was tested in clinical trial numbers GS-98-437 and GS-98-438.", "snippet_links": [{"key": "clinical-trial", "type": "clause", "offset": [74, 88]}], "hash": "42b76084fbdcb99960da669bbb65fb48", "id": 5}, {"size": 3, "samples": [{"hash": "3m2FtOFHW7j", "uri": "/contracts/3m2FtOFHW7j#current-product", "label": "Merger Agreement (Salix Pharmaceuticals LTD)", "score": 25.5174541473, "published": true}], "snippet": "means the Product in the form, formulation and dosage strengths (200mg and 600mg) existing as of the Effective Date.", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [6, 17]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [91, 115]}], "hash": "6a7fd41a8546a84fc1bceafdff76db91", "id": 6}, {"size": 2, "samples": [{"hash": "bCHJALEwVZM", "uri": "/contracts/bCHJALEwVZM#current-product", "label": "License Agreement (Biodelivery Sciences International Inc)", "score": 29.2409305573, "published": true}, {"hash": "ghiUUAwHLoZ", "uri": "/contracts/ghiUUAwHLoZ#current-product", "label": "License Agreement (Biodelivery Sciences International Inc)", "score": 28.8548946381, "published": true}], "snippet": "means that certain Licensed Product that is the subject of NDS Dossier ID: 183069 (the \u201cCurrent Product NDS\u201d).", "snippet_links": [{"key": "licensed-product", "type": "definition", "offset": [19, 35]}, {"key": "subject-of", "type": "clause", "offset": [48, 58]}], "hash": "4aa65097c5ef15b2c096b5788eab7b8a", "id": 7}, {"size": 2, "samples": [{"hash": "9YbWCxbSkHk", "uri": "https://www.sec.gov/Archives/edgar/data/1585608/000104746917004307/a2232537zex-10_63.htm", "label": "Bill of Sale (Jaguar Animal Health, Inc.)", "score": 19.4880218506, "published": false}, {"hash": "4ukh9iclxWm", "uri": "https://www.sec.gov/Archives/edgar/data/1585608/000104746917003695/a2232030zex-10_63.htm", "label": "Transfer and Transition Agreement (Jaguar Animal Health, Inc.)", "score": 19.3976726532, "published": false}], "snippet": "means that certain pharmaceutical product containing the Licensed Compound that is currently marketed by Salix in the Territory pursuant to the NDA under the brand name \u201cFulyzaq\u00ae\u201d.", "snippet_links": [{"key": "pharmaceutical-product", "type": "clause", "offset": [19, 41]}, {"key": "licensed-compound", "type": "definition", "offset": [57, 74]}, {"key": "by-salix", "type": "clause", "offset": [102, 110]}, {"key": "in-the-territory", "type": "clause", "offset": [111, 127]}, {"key": "pursuant-to-the", "type": "definition", "offset": [128, 143]}, {"key": "brand-name", "type": "definition", "offset": [158, 168]}], "hash": "e9472019b323223bd91361288683155c", "id": 8}, {"size": 2, "samples": [{"hash": "4WOuccvefyi", "uri": "/contracts/4WOuccvefyi#current-product", "label": "License Agreement (Eagle Pharmaceuticals, Inc.)", "score": 27.9130725861, "published": true}, {"hash": "dntJvBuWLis", "uri": "/contracts/dntJvBuWLis#current-product", "label": "License Agreement (Eagle Pharmaceuticals, Inc.)", "score": 27.1601638794, "published": true}], "snippet": "means the product with the composition and formulation described in the NDA with the number 205934, as may be amended.", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [6, 17]}], "hash": "006688aed6a2569bd17fd4945f919f74", "id": 9}, {"size": 2, "samples": [{"hash": "a0SJ2FRRvQf", "uri": "/contracts/a0SJ2FRRvQf#current-product", "label": "Exclusive License and Co Funding Agreement (Arrowhead Pharmaceuticals, Inc.)", "score": 32.0937728882, "published": true}, {"hash": "iJ0Zx4usaJZ", "uri": "https://ir.arrowheadpharma.com/static-files/14c571db-cd97-4afe-af04-be9f5636b1c4", "label": "ir.arrowheadpharma.com", "score": 10.5468854904, "published": false}], "snippet": "means the Product containing ARO-AAT that is the subject of the New Clinical Trial.", "snippet_links": [{"key": "the-product", "type": "clause", "offset": [6, 17]}, {"key": "subject-of-the", "type": "clause", "offset": [49, 63]}, {"key": "clinical-trial", "type": "clause", "offset": [68, 82]}], "hash": "245dcf7d28c5dd78cda96c7263625ddf", "id": 10}], "next_curs": "ClwSVmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjgLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIYY3VycmVudC1wcm9kdWN0IzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"size": 69, "snippet": "means any (i) Sensor Product or Control Product, or any component thereof, that was manufactured, marketed, sold, offered for sale, distributed or otherwise transferred by the Business, or with respect to which the Business has substantially completed its development efforts, as of the Closing Date and (ii) future Sensor Product, Control Product or component that is an extension, modification, derivation, replacement or successor of such Sensor Product, Control Product or component and does not infringe or misappropriate Intellectual Property Rights of a third party in a manner that is materially different from its predecessor.", "title": "Current Product", "id": "current-product", "examples": ["Seller shall invoice Buyer within 60 days after each shipment of such <strong>Current Product</strong> for the applicable Have Made Costs for the <strong>Current Products</strong> included in such shipment.", "Buyer shall not, however, be required to recall or destroy price lists, literature or advertising for the <strong>Current Product</strong> bearing Seller Trademarks and Tradenames.", "The Acquired Assets constitute all of the rights, property and assets that are owned and controlled by Seller or any of its Affiliates as of the Closing Date and are necessary for the development and commercialization of the <strong>Current Product</strong>.", "Neither Seller nor any of its Affiliates has received any written notice from any Governmental Authority claiming that the research, development, manufacture, or use of BMN-673 and the <strong>Current Product</strong> is not in material compliance with all applicable Laws.", "None of the Excluded Assets (other than certain employees of Seller or any of its Affiliates) are material to the development and commercialization of the <strong>Current Product</strong>.", "Salix and Napo each shall keep all records and reports required to be kept by Applicable Laws, and each will make its facilities available at reasonable times during regular business hours for inspection by representatives of governmental or Regulatory Authorities with respect to the <strong>Current Product</strong>.", "Except as set forth in this Agreement with respect to the Licensed Compound and the <strong>Current Product</strong> in the Territory, Salix shall have no rights or obligations with respect to the Licensed Compound or Licensed Products anywhere in the world for any purpose.", "With respect to Inventory of <strong>Current Product</strong> transferred to Napo hereunder, Napo may re-label such Inventory with a National Drug Code obtained from the FDA for the <strong>Current Product</strong> by Napo and in Napo\u2019s name, and thereafter Napo shall have the right to use and sell such Inventory with such re-labeling.", "There is no fact, event or condition known to InSite that materially adversely affects the <strong>Current Product</strong> that has not been set forth in this Agreement or disclosed by InSite to Inspire in writing.", "With respect to the Licensed Products, upon assignment of the <strong>Current Product</strong> NDA to Collegium (\u201cNDA Assignment\u201d), Collegium agrees, at its sole cost and expense, to maintain all Marketing Authorizations and Governmental Approvals in the Territory throughout the Term, including submitting any supplemental applications, annual reports, variations or renewals thereof that are required by Applicable Law to be obtained in order to maintain the Marketing Authorizations and Governmental Approvals."], "related": [["licensed-product", "Licensed Product", "Licensed Product"], ["generic-product", "Generic Product", "Generic Product"], ["diagnostic-product", "Diagnostic Product", "Diagnostic Product"], ["end-product", "End product", "End product"], ["hemp-product", "Hemp product", "Hemp product"]], "related_snippets": [], "updated": "2026-09-04T05:52:11+00:00"}, "json": true, "cursor": ""}}